4D Molecular Therapeutics (FDMT) Operating Margin (2020 - 2026)
4D Molecular Therapeutics (FDMT) reported Operating Margin of 2416.15% for Q1 2026, up 38059100.0% year-over-year from N/an in Q1 2025, and down 14071.45% quarter-over-quarter from 17.29% in Q4 2025.
4D Molecular Therapeutics (FDMT) Operating Margin (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of Operating Margin data on file, last reported at 2416.15% in Q1 2026.
- Operating Margin for Q1 2026 came in at 2416.15%, up 38059100.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 203.47% (up 88382262.0% YoY), and the FY2025 annual result was 187.24%, up 50749114.0% from the prior year.
- Operating Margin fell to 2416.15% in Q1 2026 per FDMT's latest filing, from 17.29% in the prior quarter.
- Over five years, Operating Margin peaked at 192905.26% in Q4 2023 and troughed at 5611700.0% in Q4 2024.
- A 5-year average of 529953.49% and a median of 13446.03% in 2023 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2024 and 2025: Operating Margin tumbled 580460526 bps in 2024, then soared 561171729 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 2303.13% in 2022, then jumped by 8476 bps to 192905.26% in 2023, then sank by 3009 bps to 5611700.0% in 2024, then surged by 100 bps to 17.29% in 2025, then tumbled by 14071 bps to 2416.15% in 2026.
- Business Quant data shows FDMT's Operating Margin at 2416.15% in Q1 2026, 17.29% in Q4 2025, and 67983.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | -2,416.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,416.15% |
| Dec 31, 2025 | 17.29% |
| Sep 30, 2025 | -67,983.33% |
| Jun 30, 2025 | -396,373.33% |
| Mar 31, 2025 | -383,007.14% |
| Dec 31, 2024 | -5,611,700.00% |
| Sep 30, 2024 | -1,704,400.00% |
| Jun 30, 2024 | -849,120.00% |
| Mar 31, 2024 | -136,200.00% |
| Dec 31, 2023 | 192,905.26% |
| Sep 30, 2023 | -69.16% |
| Jun 30, 2023 | -13,446.03% |
| Mar 31, 2023 | -10,102.68% |
| Dec 31, 2022 | -2,303.13% |
| Sep 30, 2022 | -5,299.00% |
| Jun 30, 2022 | -17,546.91% |
| Mar 31, 2022 | -2,165.05% |
| Dec 31, 2021 | -26,917.39% |
| Sep 30, 2021 | -1,658.93% |
| Jun 30, 2021 | -52.10% |